BOUL: Instrument sales surged 17% but lower prices and costs led to margin decline; cash flow turned positive

About this update from Boule Diagnostics Ab

Q2 saw a 3.3% organic sales decline, but instrument unit sales rose 17% year-over-year, with 5-Part instrument sales more than doubling at lower prices. Operating expenses dropped 47%, and positive operating cash flow was achieved, despite margin pressures from currency and costs. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Boule Diagnostics Ab